NRG GU012 (SAMURAI): Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma Receiving Immunotherapy
Renal
Recruiting
Multiple locations
Disease: Renal
Eligibility Criteria: None
NCT: 05327686
Eligibility:
-
Renal Cell Carcinoma
-
Node positive unresectable (TxN1Mx) or metastatic (TxNxM1)
-
Must have IMDC intermediate (1-2 factors) or poor risk disease (≥3 factors)
-
Not recommended or refused immediate cytoreductive nephrectomy
-
Candidate for SOC therapy with either IO-IO or IO-VEGF combination
-
Primary renal tumor 20cm or less
Have questions about participation?
Our clinical research team is happy to answer questions about eligibility, the study process, or next steps.
Contact the Research Team